BioCryst: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:BioCryst logo.png|right|225px]] | [[Image:BioCryst logo.png|right|225px]] | ||
'''BioCryst Pharmaceuticals Inc.''' (NASDAQ:BDRX) is a pharmaceutical company | '''BioCryst Pharmaceuticals Inc.''' (NASDAQ:BDRX) is a pharmaceutical research company founded in [[1986]] in [[Birmingham]] as a spin-off of [[UAB]] research. It went public in [[1994]] and is currently headquartered in Raleigh, North Carolina, with research operations at its "Discovery Research Center and Laboratory Center of Excellence" in Birmingham. | ||
Formerly headquartered at 2190 [[Parkway Lake Drive]], BioCryst develops and manufactures various types of perscription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208. | |||
The current CEO is [[Jon Stonehouse]], who succeeded co-founder [[Charles E. Bugg]] after his retirement in [[2007]]. | |||
==Products== | ==Products== | ||
| Line 11: | Line 13: | ||
* Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II) | * Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II) | ||
* BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I) | * BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I) | ||
* | * Peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I) | ||
* BCX-4208 Oral, for treatment of Hepatitis C | * BCX-4208 Oral, for treatment of Hepatitis C | ||
| Line 17: | Line 19: | ||
* BioCryst Pharmaceuticals, Inc. (2005) ''[http://www.biocryst.com/pdf/biocryst_2005_ar.pdf Corporate Report 2005]'' (PDF) - accessed September 21, 2006 | * BioCryst Pharmaceuticals, Inc. (2005) ''[http://www.biocryst.com/pdf/biocryst_2005_ar.pdf Corporate Report 2005]'' (PDF) - accessed September 21, 2006 | ||
* [http://secfilings.nasdaq.com/edgar_conv_html%2f2005%2f03%2f16%2f0001206774-05-000364.html#FIS_BUSINESS BioCryst Pharmaceuticals Inc.] corporate spotlight at NASDAQ. - Accessed September 21, 2006 | * [http://secfilings.nasdaq.com/edgar_conv_html%2f2005%2f03%2f16%2f0001206774-05-000364.html#FIS_BUSINESS BioCryst Pharmaceuticals Inc.] corporate spotlight at NASDAQ. - Accessed September 21, 2006 | ||
* Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." ''Birmingham News''. | * Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." ''Birmingham News'' | ||
* DeButts, Jimmy (November 13, 2009) "BioCryst sees healthy future after flu drug." ''Birmingham Business Journal'' | |||
* Piper, Ben (October 13, 2010) "BioCryst Pharmaceuticals Inc. moving HQ to North Carolina." ''Birmingham Business Journal'' | |||
==External links== | ==External links== | ||
| Line 23: | Line 27: | ||
[[Category:Major corporations]] | [[Category:Major corporations]] | ||
[[Category:1986 establishments]] | |||
[[Category:Pharmaceuticals]] | [[Category:Pharmaceuticals]] | ||
[[Category:Parkway Lake Drive]] | |||
Revision as of 17:54, 13 October 2010
BioCryst Pharmaceuticals Inc. (NASDAQ:BDRX) is a pharmaceutical research company founded in 1986 in Birmingham as a spin-off of UAB research. It went public in 1994 and is currently headquartered in Raleigh, North Carolina, with research operations at its "Discovery Research Center and Laboratory Center of Excellence" in Birmingham.
Formerly headquartered at 2190 Parkway Lake Drive, BioCryst develops and manufactures various types of perscription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.
The current CEO is Jon Stonehouse, who succeeded co-founder Charles E. Bugg after his retirement in 2007.
Products
BioCryst is developing the following drug treatments:
- Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
- Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
- Fodosine Oral, for treatment of chronic lymphocytic leukemia (Phase I/II)
- Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II)
- BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I)
- Peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I)
- BCX-4208 Oral, for treatment of Hepatitis C
References
- BioCryst Pharmaceuticals, Inc. (2005) Corporate Report 2005 (PDF) - accessed September 21, 2006
- BioCryst Pharmaceuticals Inc. corporate spotlight at NASDAQ. - Accessed September 21, 2006
- Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." Birmingham News
- DeButts, Jimmy (November 13, 2009) "BioCryst sees healthy future after flu drug." Birmingham Business Journal
- Piper, Ben (October 13, 2010) "BioCryst Pharmaceuticals Inc. moving HQ to North Carolina." Birmingham Business Journal
External links
- BioCryst Pharmaceuticals Inc. website